Agent for prevention of mastitis in dairy cows in dry period

FIELD: veterinary medicine.

SUBSTANCE: agent for prevention of mastitis in dairy cows in the dry period, characterised in that it contains as ingredients the polymer PVP/VA, silicone, polyhexamethylene biguanide, ethyl alcohol, glycerol - as emollient component, gelation agents - triethanolamine and carbopol and purified water in the following ratio of ingredients, %: polymer PVP/VA 9-10; silicone 5-6; ethyl alcohol 35-40; polyhexamethylene biguanide 0.008-0.01; glycerol 5; gelation agents - triethanolamine and carbopol 0.1; purified water - the rest.

EFFECT: method enables to minimise or eliminate the use of chemotherapeutic agents, antibiotics and their derivatives, sulphonamides, nitrofurans and eliminate the side effect of the agent on animal body, as well as to reduce the number of visits of the veterinarian during the dry period of cows, to improve the preventive efficacy.

1 tbl, 3 ex

 

The proposed tool relates to the field of veterinary medicine and is intended, in particular, to pharmacoprophylaxis mastitis in cows after their transfer into the dead wood.

The mammary gland of cows located in deadwood, vulnerable to mastitis pathogens, and the peak incidence occurring, particularly in the first 2-3 weeks after cessation of milking, i.e. degenerative phase postlactational involution of the udder.

Known introduction all part of the udder of cows immediately after cessation of milking a special dosage forms of antibiotics, for example, napisala DC, orbenin DC (B. Boddle, S. Niskersson. Dry Cows therapy. I. Dairy Sci., 1996. No. 1. - P. 253-257). Once their application protects the udder from pathogens for 2-4 weeks.

In the countries of Western Europe and the United States, these funds are very popular with farmers, because thanks to the introduction of these funds cow stops milked, much easier than running a highly productive cows and reduces the number of visitati veterinary specialist for treatment about mastitis. However, their use in herds with an annual milk yield below 4500 kg and in herds with a classic launch system (gradual cessation of milking cows, does not justify the costs (OF Shakirov. Single run cows in loose-content / J. Dairy and beef scatologist is about, 2005. No. 7. P.35-38).

Known adhesives to protect the udder dry cows from the penetration of microorganisms from the external environment, such as Duroplast. (V.M. Kartashov, Zabelin Y.A. Prevention of mastitis in the period of deadwood. // Veterinary - 1984 - No. 1 - P.48.) Practical applications they received, obviously, because of the one-sidedness of protective actions - channel of the nipple is protected from the external environment that does not provide a reliable prevention of mastitis in cows.

In addition, a well-known treatment of the teats of the udder during the launch of the film-antiseptic coating for the prevention of mastitis in the dry period (Roman L.G. Film-antiseptic coating - tool profilactic mastitis dry cows / L.G. novel, N.I. Polyantsev // Scientific journal. Proceedings of the Kuban state agrarian University. - Krasnodar. - 2008. - Vol. No. 6 (15). - P.116-119.). Disadvantages: low therapeutic efficacy.

The closest analogue of the proposed tools is film-antiseptic coating, which contains in its composition godisgoodalltime and biopolymer. The biopolymer is produced by the interaction of urea, formaldehyde, glycerol, followed by adding 50%aqueous solution of polyvinylpyrrolidone.

The disadvantages of this prototype are as follows:

- handling the teats of the udder produce repeatedly, mainly in the 1st and 8th day./p>

- the integrity of the protective coating is small, the film on the teat remains no more than 5-7 days.

Objectives: to Develop a tool for the prevention of mastitis in cows during the period of dead wood without the use of antibiotics and other chemotherapeutic agents, leading to the culling of milk, and reduce the number of visitati veterinary specialist to animals, to improve preventive effect of mastitis in dry cows.

The essence of the proposed means of preventing mastitis in dairy cows in the period of deadwood includes the use of a polymeric film and is characterized by the fact that the tool as an antiseptic contains polyhexamethyleneguanidine (0,008-0,01%) and ethyl alcohol (35-40%), and a film coating polymer (9-10%), for example, water-soluble polymer PVP/VA, silicone (5-6%) and glycerol (5%) as the softening component, and geleobrazovanie - triethanolamine (0.1%) and carbopol (0,1%). Water is included in (39-46%) as solvent and provide sufficient gel consistency.

Effect: the proposed method eliminates the use of chemotherapeutic agents, to eliminate the use of antibiotics and their derivatives, sulfonamides, nitrofuranov and thus eliminating the side effects of the drug on the organism of animals and reduce the number of visitati veterinarian is in a period of dead cows, to improve prophylactic efficacy.

Polyhexamethyleneguanidine bactericidal agent with a wide spectrum of action. At relatively low concentrations of bactericidal substances bacteriostatic; at higher concentrations sharply bactericidal. Ethyl alcohol has the properties of disinfectant, anti-inflammatory, analgesic and distracting tools.

Water-soluble polymer and silicone provide education on the skin surface of a thin elastic film which isolates it from contact with the external environment.

Glycerin can hold some water, protecting the skin from excessive moisture loss.

Triethanolamine and carbopol is used to give the tool a gel-like consistency, thereby decreasing the flow of funds and commit it on the nipple of the cow.

Stated the vehicle was prepared as follows:

In measuring the capacity of the charge according to the recipe purified water and add heliobacter carbopol, for its uniform distribution in the water continuously stirring for 40 minutes then in a container with a mixture of carbopol and water contribute polymer, stirring constantly. Then, after thorough mixing the mixture is brought to a temperature of 40-45°C and add glycerine, silicone, and triethanolamine, good premesis the Ute and allow to cool to room temperature. After cooling, to the resulting mixture add the alcohol, polyhexamethyleneguanidine and purified water. After receiving a mixture of all components of the obtained gel is thoroughly mixed.

The resulting tool is used as follows: during startup, immediately after the last milking, wipe teats of the udder with a dry cloth or towel and use plastic cups put this tool, spending 2-3 grams of the drug on the animal, after which the cows define the group of dead wood.

Conducted a comparative evaluation of the protective properties of the film coating. From the number of cows with ended lactation formed three equal groups, each consisted of 50 goals: 1 - single skin treatment teats of the udder of the stated means; 2nd - twice, with a week's interval, processing the teat skin of the udder film-antiseptic coating (PAP); 3-I - without the use of tools pharmacoprophylaxis.

In experimental animals 3 groups on the 15th day dry period and after calving examined mammary gland clinical methods and production test reaction results are shown in the table.

In the 3rd group (negative control) mastitis on the 15th day dry period was found to have 13 goals, including nine clinically pronounced and four - subclinical. In the period from 15 days before calving sick 4 orovi. Thus, the total incidence was 34%.

Table
Comparative analysis of the results of the use of the proposed tools for the prevention of mastitis in cows during the period of deadwood
GroupnProphylacticIdentified cases of mastitis cows
On the 15th dayFor the entire period of deadwood
Clinical mastitisSubclinical mastitisClinical mastitisSubclinical mastitis
Qty%Qty%Qty%Qty%
1st50The claimed tool0 0243624
2nd50DADS482451036
3rd50-918481224510

In the 2nd group on the 15th day mastitis was detected in six cows and four clinically distinct and two - subclinical. In the subsequent period ill 2 more cows. As a result, the incidence decreased to 16% or 2-fold, compared to control.

In the 1st group mastitis on the 15th night found in 2 cows, with only subclinical. During the period of snags found 5 cows with mastitis, three with clinical and two with subclinical, which amounted to a total of 10% of the population. From this it follows that when using the proposed drug preventive effect is 1.6 times higher compared to the POPES.

Example 1. In a measuring Cup (1000 ml) was filled with 300 ml of purified water and added to 1 g of heleonastes of carbopol, for its uniform distribution in water was carried out by constant stirring for 40 minutes After that the flask with a mixture of carbopol and water introduced 10 g of the polymer, stirring constantly. Then, after thorough mixing, the resulting mixture is brought to a temperature of 40-45°C and added 5 g of glycerin, 5 g of silicone and 1 g of triethanolamine, well mixed and allowed to cool to room temperature. After cooling, to the resulting mixture was adding 400 ml of ethanol, was added 0.08 g polyhexamethyleneguanidine and brought to the label (1000 ml) of purified water. After receiving a mixture of all components of the obtained gel is thoroughly mixed. The resulting composition was Packed in airtight containers prior to use.

Example 2. According to the described technology in example 1 was taken per 1000 ml: 9 g of polymer, 6 g of silicone, 350 ml of ethanol, 0.1 g polyhexamethyleneguanidine, 5 g of glycerol, 1 g of carbopol, 1 g of triethanolamine, and the rest with purified water. The resulting composition pacaveli in airtight containers prior to use.

Example 3. Cow Mug (inv. No. 893) 2007 birth started 19.07.2012, Immediately after the last milking of the cow udder nipples rubbed with a dry cloth and using a plastic Cup to handle nipple inflicted received the first tool on the nipples. Immediately after spraying the teats of a cow is identified in a group of dead wood. Subsequent daily monitoring of the condition of the udder of the animal showed that processed the nipple has a transparent film, which stayed on the nipple of the udder prior to calving. Immediately after calving conducted a survey of the animal. Animal mastitis is not sick. The reaction with the test Diagnostica the hidden form of mastitis was negative.

Tool for the prevention of mastitis in dairy cows in the dry period, characterized by the fact that the quality of the ingredients contains polymer PVP/VA, silicone, polyhexamethyleneguanidine, ethyl alcohol, glycerin as a cushioning component, geleobrazovanie - triethanolamine and carbopol and purified water in the following proportions of ingredients, %:

polymer9-10
silicone5-6
ethyl alcohol35-40
polyhexamethyleneguanidine0,008-0,01
glycerin5
geleobrazovanie - triethanolamine and carbopol0.1
purified the ode rest



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention refers to the veterinary science, particularly to substances used in treating purulent-necrotic involvements of bovine's distal extremities, including digital dermatitis. A preparation for treating bovine digital dermatitis in the form of an ointment consists of an excipient, containing an ointment base, and an active ingredient - zinc oxide and copper sulphate in the following proportions, wt %: zinc oxide 9-11, copper sulphate 35-45, the ointment base - the rest.

EFFECT: invention provides higher clinical effectiveness with cost cutting for the ointment preparation.

1 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to otorhinolaryngology, and may be used for the preoperative preparation of the patients suffering a perforated nasal septum. Intranasal silicone splints are placed 10 days before the operation. The splint is incised from one side within a perforation border. A 30° endoscope is used to assist a 7-day daily nasal perforation rinsing with chlorhexidine. A suction unit is used to evacuate mucosal secretion; synthomycin ointment is introduced through the incision in the silicone splint to the perforation region. The nasal cavity is irrigated daily with antiseptic and vasoconstrictive preparations. On the 7th day, the intranasal splints are removed.

EFFECT: method enables relieving the mucosal inflammation within the perforation, promotes the prolonged drug retention in the introduction place, ensures avoiding an overlay of a secondary infection, improves the functional state of ciliated epithelium.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to surgical dentistry and maxillofacial surgery, and is applicable in maxillary sinusotomy with fistula repair. A mucous membrane is incised to a bone under an intubation narcosis after a two-fold preparation of a surgical area. A D-shaped flap is cut out within an alveolar socket of an extracted tooth to be extended along a mucobuccal fold of an upper jaw on one side to a second incisor, and on the other side - to a third molar. The flap together with the periosteum is separated and retracted upwards with exposing a canine fossa and the alveolar socket of the extracted tooth. A hole is created within the canine fossa. Pathologically changed tissues or all sinus mucosa is scooped with a bone curette through the created hole. The alveolar socket of the extracted tooth is inspected. After the cavity has been scooped, an artificial hole is created towards a nasal cavity through an inferior nasal meatus. The sinus cavity is packed with a iodoform cotton swab; an end of the cotton swab is laid thoroughly on a sinus bottom, namely within the defect; the end of the cotton swab is brought out into a nose. A mucoperiosteal flap is mobilised within the alveolar socket of the extracted tooth, laid on the alveolar socket; the wound is closed completely. In the postoperative period, the cotton swab is removed from the sinus on the 9-10th day. The sutures are removed on the 10-11th day.

EFFECT: method enables reducing an incidence of recurrent oroantral communications in the postoperative period ensured by a compact packing of the sinus, and the antiseptic and regeneration effect of iodoform on the maxillary sinus.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to veterinary science, namely to obstetrics and gynaecology. A preparation for treating and preventing sub-clinical, clinical, acute and chronic mastitis in farm and domestic animals contains an active substance that is - triphenyl-(3,5-di-tert-butyl-4-hydroxybenzyl)phosphonium bromide and a pharmaceutically acceptable carrier that is Vaseline in ratio 1:2000.

EFFECT: invention provides the higher antimicrobial effectiveness and the lower toxicity of the ointment with the lower concentration of the active substance.

3 tbl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to an antiseptic drug with haemostatic action for wound cleaning. The drug contains ingredients in the following ratio, wt %: an antimicrobial substance - 0.01-3, an active complex - 1-25, glycerol - 2-35 and water - up to 100. The antimicrobial substance is specified in a group consisting of cetyl pyridinium or cetyl methyl ammonium halogenide, chlorhexidine, miramistin and other quaternary bases applicable in medical practice to treat burns and to clean open wounds, and the active complex is presented by a haemostatic preparation in the form of a mixed-ligand chelated complex of zinc, ethylene diamine tetraacetic acid and ε - aminocapronic acid. The invention also refers to a method for preparing the antiseptic drug with haemostatic action. The method consists in the fact the active complex is prepared in a water-glycerol mixture while stirring by dissolving ε - aminocapronic acid, then zinc oxide, adding powdered ethylene diamine tetraacetic acid and after dissolved completely, adding a liquid solution of the antimicrobial substance in the water-glycerol mixture.

EFFECT: preparing the antiseptic drug with haemostatic action for wound cleaning.

2 cl, 9 ex

FIELD: medicine.

SUBSTANCE: invention refers to pharmaceutical industry and represents a preparation possessing the anti-inflammatory action, stimulating the mucosa regeneration, and containing magnesium-chloride mineral bischofit brine 1.27±0.01 g/ml with normalised specific gravity, slastiline, menthol, thymol, and a stabilising agent differing by the fact that it contains magnesium-chloride mineral bischofit brine free from technogenic impurities, with the ingredients in the preparation are taken in specific proportions, g.

EFFECT: reducing acute daily oral toxicity in 1,7-1,9 times.

1 tbl

FIELD: biotechnologies.

SUBSTANCE: invention refers to derivatives of oxazolopyrimidine in any of their stereoisomeric forms, or in the form of a mixture of stereoisomeric forms specified in Claim 1.

EFFECT: oxazolopyrimidine derivatives having agonistic activity in relation to Edg-1 receptor.

5 tbl, 319 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to general surgery, and can be applied in prevention of purulent-inflammatory complications of anterior abdominal wall wounds in case of strangulated ventral hernias. For this purpose, 10% solution of colloidal nanosilver is introduced into operation wound after elimination of strangulation, with preliminary injections on perimetre of hernial orifice edges in dose 0.1 ml of solution per 1 cm2 of aponeurosis. After that, after fixation of synthetic implant, injections are made along the line of sutures on periphery in dose 0.1 ml per 1 cm2 of suture. After that, subcutaneous adipose cellular tissue is infiltrated with solution of colloidal nanosilver in dose 0.1 ml of solution per 1 cm2 of wound.

EFFECT: method ensures considerable reduction of risk of development of purulent-inflammatory complications in patients with said pathology, as well as acceleration of processes of tissue reparation due to application of biologically active colloidal solution of nanosilver, producing selective impact only on pathogenic microorganisms, on all layers of anterior abdominal wall and zone of synthetic implant fixation.

5 cl, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely purulent surgery, and may be used for treating infected wounds. That is ensured by surgical treatment of suppurative focuses and exsection of necrotised tissues. Then the whole wound surface is treated with 10% colloidal nanosilver. The subcutaneous fat is infiltrated with 10% colloidal nanosilver at 0.1 ml of the solution per 1 cm2 of the wound. Additionally, the wound is covered with a sterile 10% colloidal nanosilver wipe.

EFFECT: method enables reducing the length of wound granulation and epithelisation ensured by using the biologically active colloidal nanosilver solution coating all wound layers and rendering selective action on pathogens only.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, specifically to an agent showing antimicrobial activity.

EFFECT: agent possessing antimicrobial action and representing robinia (Robinia pseudaacacia L) seed essence prepared by collecting the seeds in October and extracting them three times in petroleum benzene under certain conditions.

2 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the general mixture for production of rapidly decomposable tablets in the process of direct tabletting. The claimed mixture contains 90-98 weight parts of the pulverised mannit with water content from 0.3 to 1% by weight and 2-10 weight parts of cross-linked sodium-carboxymethylcellulose. The general mixture has the area of BET surface in the range from 1.5 to 4.0 m2g. The invention also relates to application of the said general mixture for preparation of tablets, including vitamins, mineral substances, microelements, functional food components, plant components and extracts, synthetic and natural dyes and flavours, as well as substances, possessing pharmacological action.

EFFECT: invention relates to the tablet composition, which contains an active compound and/or a flavour, and is prepared with application of the general mixture as a shape-forming material/ The invention ensures facilitation of direct tablet pressing, as well as obtaining tablets with the improved hardness.

14 cl, 1 dwg, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry, and represents a composition containing polyethylene glycol 30 to 150 g, an ascorbic acid ingredient 3 to 20 g specified in ascorbic acid, ascorbic acid salt, or a mixture thereof, alkali or alkali earth sulphate, and at least one electrolyte specified in sodium chloride, potassium chloride, and sodium hydrocarbonate in one litre of an aqueous solution; it additionally contains flavouring agents and is effective in the colon cleansing for preparing for an endoscopy, particularly a colonoscopy. The invention contains a unit dose for preparing the colon cleansing solution, the colon cleansing solution, the method for preparing and using the same, and the kit for preparing and using the colon cleansing solution.

EFFECT: composition is safer than the standard colon cleansing compositions of sodium phosphate, and thereby may be used for the patients exposed to an elevated risk of using the composition of sodium phosphate, and is more tolerable than the standard compositions of PEG (polyethylene glycol) leading to a better compliance with the regimen and providing the effective use by outpatients.

48 cl, 6 ex, 29 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to granules as a laxative, containing particles of magnesium oxide of formula Mg2+1-xZn2+x)O (1) with the average diameter of secondary particles 0.1-25 mcm and apparent specific volume 3-20 ml/g. In formula (1) X represents number from 0 to 0.02, content of magnesium oxide particles constitutes from 80 to 95 wt %. Granules also include mannitol and carmellose and have the average particle diameter 0.2-0.4 mm and bulk density 0.4-0.7 g/ml. Content of particles in granules, which have particle diameter from less than 500 mcm to not less than 355 mcm, constitutes from 30 to 45 wt %, content of particles, which have particle diameter from less than 355 mcm to not less than 180 mcm constitutes from 40 to 50 wt %, content of particles, which have particle diameter from less than 180 mcm to not less than 150 mcm, constitutes from 10 to 28 wt %.

EFFECT: granules of magnesium oxide possess good solubility, attractive taste and outlook and do not leave sense of roughness in the oral cavity.

4 cl, 7 tbl, 2 dwg, 7 ex

FIELD: chemistry.

SUBSTANCE: biocidal composition for soaking napkins contains benzethonium chloride, sodium hydroxymethylglycinate, glycerine, decyl polyglucose, niacinamide, liposentol hydro, phenylmethanol and distilled water. Components are used in a defined ratio given in wt %.

EFFECT: invention improves biocidal properties of the napkin soaking composition.

3 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: there are presented: using nalbuphine salt in the form of a hydrophilic emulsion suppository for treating moderate to severe pain syndrome, a pharmaceutical composition for the same application in the form of suppositories comprising nalbuphine hydrochloride as an active substance and a hydrophilic emulsion base in the following ratio, g/100 g of the composition: nalbuphine hydrochloride 0.0125-5.00, hydrophilic emulsion base up to 100 g, and a method for preparing the same.

EFFECT: effective and prolonged analgesic action with no laxative action has been shown.

7 cl, 3 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to using ultradisperse silver-containing systems as anti-inflammatory, anti-exudative and wound-healing agents. The ultradisperse silver-containing systems represent zero-valent silver metal nanocomposites at particle size 10-25 nm stabilised with arabinogalactine and its sulphated derivative. The invention also refers to an agent for wound and burn healing having anti-inflammatory, anti-exudative, wound-healing and antimicrobial activity, comprising said silver nanocomposites as a pharmacologically active substance and additionally containing carbomer, triethanolamine, glycerol or 1,2-propylene glycol and water. The agent is presented in the form of topical hydrophilic gel. The invention also refers to using the above agent for wound and burn healing in an individual in need thereof.

EFFECT: declared invention provides creating the hydrophilic gels of silver nanocomposites that are applicable for wound and burn healing.

3 cl, 8 dwg, 7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, particularly dermatology, namely to a film coating solution for the removal of pathological nail keratoderma, containing: 10 to 20% of urea, 8 to 12% of the film coating polymer Eudragit E100, 45 to 50% of ethanol, 1 to 5% of propylene glycol, 0.5 to 1% of diethylphthalate, and water up to 100%.

EFFECT: invention provides preparing a transparent film coating high-urea solution.

5 cl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, namely to pharmacy and concerns the development of an ointment containing mechanically activated amorphous or amorphous crystalline calcium gluconate, and may be used in the integrated treatment of skin diseases related to calcium deficiency, namely to the integrated treatment of dermatoses: psoriasis, atopic dermatitis, eczema and keratoderma. As an active ingredient, the ointment contains mechanically activated amorphous or amorphous crystalline calcium gluconate; an ointment base is Vaseline, glycerol, emulsifier No.1, Lutrol F 127 and purified water in the following proportions, wt %: mechanically activated amorphous or amorphous crystalline calcium gluconate-5.0; Vaselin-10.0; glycerol-10.0; emulsifier No.1-8.0; lutrol F 127-2.0 and purified water up to 100.0.

EFFECT: ointment possesses high therapeutic activity, provides the uniform release of the active ingredient that is mechanically activated amorphous or amorphous crystalline calcium gluconate, the manifested prolonged action and applicability by the patient.

4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to medicine and pharmaceutical industry and describes an inhalation formulation in the form of aerosol for treating bronchial asthma and chronic obstructive pulmonary disease, containing beclomethasone dipropionate, a solvent an adjuvant and a propellant; the solvent is presented by absolute ethyl alcohol, while the adjuvant is an aerosol particle size control consisting of triethyl citrate and perfluorodecaline; the propellant is 1,1,1,4 tetrafluoroethane (HFA-134a) and/or 1,1,1,2,3,3,3-heptafluoropropane (HFA-227ea). The formulation has a higher efficacy.

EFFECT: developing the inhalation formulation in the form of aerosol for treating bronchial asthma and chronic obstructive pulmonary disease.

9 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: described is injected formed in situ depot-composition, which includes absorbable polymer, polyethyleneglycol with molecular weight 450<MW<650 Da and with end groups, selected from methoxy and ethoxy, characterised by temperature of consolidation between 8° and 20°C, pharmaceutically active substance and, optionally, auxiliary substance. Pharmaceutically active substance is selected from small organic molecules, peptides, polypeptides, proteins, carbohydrates, oligonucleotides, DNA and RNA. Preferably, active substance is somatostatin analogue. Preferably polyethyleneglycol dimethyl ether with molecular weight 500 Da is applied.

EFFECT: compositions by invention are stable in storing, are injected without difficulties, are characterised by low haemolytic and toxic potential.

19 cl, 8 dwg, 2 tbl, 8 ex

FIELD: chemistry.

SUBSTANCE: composition includes a bactericidal substance - catapol - in amount of 2.1-2.5 wt %, zosterin in amount of 1.1-5.0 wt % and distilled water.

EFFECT: providing a composition which stimulates a reparative process in external protective tissue, having anti-inflammatory and radioprotective action.

1 tbl, 1 ex

Up!